Clinical Research Directory

Inclusion Criteria: 1. Subjects aged between 18 and 80 years. 2. Patients diagnosed with deep venous thrombosis (DVT) within 30 days of onset via color Doppler ultrasound (CDUS) or CT venography (CTV) imaging. 3. Target lesions involving the inferior vena cava, common iliac vein, external iliac vein, common femoral vein, superficial femoral vein, or popliteal vein. 4. Subjects capable of understanding the purpose of the trial, who voluntarily participate and sign an informed consent form, and are willing to undergo follow-up evaluations. Exclusion Criteria: 1. Patients diagnosed with chronic-phase deep venous thrombosis (DVT) (symptom onset \>30 days). 2. Patients with bilateral lower extremity DVT requiring thrombus removal in both limbs. 3. Patients with known bleeding disorders or bleeding tendencies (platelet count \<50×10⁹/L or INR \>3). 4. Severe hepatic or renal dysfunction Renal insufficiency (estimated glomerular filtration rate \[GFR\] \<30 mL/min); Active liver disease or ALT \>3 × upper limit of normal (ULN). 5. History of heart failure, stroke, and/or myocardial infarction within 1 month, or planned coronary/carotid revascularization or major cardiovascular/cerebrovascular surgery. 6. Target lesions involving veins with a diameter \<3 mm. 7. Patients with a life expectancy \<12 months (e.g., malignancy). 8. Patients with congenital inferior vena cava (IVC) hypoplasia/malformation or other congenital IVC/iliac vein abnormalities. 9. Allergy to anticoagulants or iodine-based contrast agents. 10. Bedridden patients unlikely to regain limb mobility within 1 month post-procedure. 11. Patients with pre-existing venous stents or IVC filters that may interfere with device deployment. 12. Patients with recurrent ipsilateral DVT. 13. Pregnant or lactating women. 14. High-risk pulmonary thromboembolism (PTE) (manifested by shock/hypotension: systolic blood pressure \<90 mmHg or \>40 mmHg drop from baseline lasting \>15 minutes). 15. Severe post-thrombotic syndrome (PTS) (defined as Villalta score \>14 points and/or skin ulcers). 16. Patients who underwent percutaneous mechanical thrombectomy within 1 month. 17. Contraindications to anticoagulation (e.g., heparin-induced thrombocytopenia \[HIT\]). 18. Contraindications to thrombolysis: Allergy to thrombolytic agents; High bleeding risk or active bleeding within 2 - 4 weeks (e.g., intracranial, gastrointestinal, or urinary tract hemorrhage); Recent major surgery, biopsy, CPR, or non-compressible puncture; Severe trauma within 2 - 4 weeks; Uncontrolled hypertension (\>160/110 mmHg); Bacterial endocarditis; Aortic dissection, aneurysm, or arteriovenous malformation. 19. History of nickel-titanium (Nitinol) alloy allergy. 20. Participation in other ongoing drug/device clinical trials. 21. Patients deemed ineligible by the investigator.